Vensana—Is Medtech Investing on the Rebound?

article image
ARTICLE SUMMARY:

After years that saw investors fleeing medical devices, a host of new funds and new entrants are breathing life into medtech start-ups. A case in point: Vensana Capital, a $225 million fund recently launched by industry veterans Kirk Nielsen and Justin Klein.

Just a few years ago, the question, “Why would anyone want to start anew fund in medtech?” would have been deemed rhetorical, with a clear implication that no one would.Indeed, not only were few VCs coming new into the space, many established medtech investors were scaling back or leaving altogether.

×

This article is restricted to subscribers only.

To continue reading, select one of the options below:

Existing Subscriber?


Sign In to continue reading.


Need Multi-User Access?

Gain access for your entire organization.

Get Quote Check to see if your company already has access

Subscribe to MedTech Strategist:

Actionable intelligence exploring the people, challenges, and opportunities impacting the global medtech community.

Subscribe to MedTech Strategist
Sign up for All-Access

Join our global community with a subscription to both MedTech Strategist and Market Pathways for one low price.

All-Access

Questions?

We're here to help! Please contact us at: